Response to 'Rituximab in membranous nephropathy'

Kidney International

Volumn 74, Issue 3, 2008, Pages 392-

  Fervenza, Fernando C ^a   Cosio, Fernando G ^a   Erickson, Stephen B ^a   Specks, Ulrich ^a   Herzenberg, Andrew M ^b   Dillon, John J ^a   Leung, Nelson ^a   Cohen, Irvin M ^a   Wochos, Daniel N ^a   Bergstralh, Eric ^a   Hladunewich, Michelle ^b   Cattran, Daniel C ^b  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CREATININE; PREDNISOLONE; RITUXIMAB;

CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFECT; FOLLOW UP; HUMAN; IMMUNOPATHOLOGY; LETTER; MEMBRANOUS GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REMISSION;

EID: 47349132109     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.237     Document Type: Letter

References (3)

1. Ring T. Rituximab in membranous nephropathy. Kidney Int 2008; 74: 391-392.
2. Harrell FE, Lee KL, Mark DB. Tutorial in Biostatistics: multivariable prognostic models: issue in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
3. Ponticelli C, Zucchelli P, Passerini P et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13.